Abstract
The use of enhancement drugs attracts considerable academic, media and public attention. Such enhancement practices range from the illicit use of medications to the legal use of caffeine. This paper reviews the risks, benefits and regulatory status of those drugs associated with both sporting and cognitive enhancement. The purpose of this paper is to forefront what we know about such drugs – and especially stimulants – prior to entering into discussion over their ethical implications. While the evidence suggests stimulants can improve sporting performance, the evidence to confirm cognitive gains is much weaker. We consequently recommend that academics, the media and regulators should avoid making exaggerated claims about such drugs, and avoid implying that their use is more common than evidence currently suggests.
Notes
Chiamulera, C. ‘Research is Needed on the Use of Cognitive Enhancer Drugs in Sport’. Journal of Science and Medicine in Sport14, no. 1 (2011): 2–3. Savulescu, J., B.Foddy, and M.Clayton. ‘Why We Should Allow Performance Enhancing Drugs in Sport’. British Journal of Sports Medicine38 (2004): 666–70. Cakic, V. ‘Smart Drugs for Cognitive Enhancement: Ethical and Pragmatic Considerations in the Era of Cosmetic Neurology’. Journal of Medical Ethics35 (2009): 611–75. Farah, M.J., J.Illes, R.Cook-Deegan, H.Gardner, E.Kandel, P.King, E.Parens, B.Sahakian, and P.R.Wolpe. ‘Neurocognitive Enhancement: What can We Do and What Should We Do?’. Nature Reviews: Neuroscience5 (2004): 421–5. Greely, H., B.Sahakian, J.Harris, R.C.Kessler, M.Gazzaniga, P.Campbell, and M.J.Farah. ‘Towards Responsible Use of Cognitive Enhancing Drugs by the Healthy’. Nature456 (2008): 702–5. van Hilvoorde, I., R.Vos, and G.de Wert. ‘Flopping, Klapping and Gene Doping’. Social Studies of Science37, no. 2 (2007): 173–200. Yesalis, C.E., and M.S.Bahrke. ‘History of Doping in Sport’. International Sports Studies24, no. 1 (2002): 42–76. WADA. ‘The World Anti-Doping Code: The 2011 Prohibited List International Standard’. 2011, http://www.wada-ama.org. Savulescu, J., B.Foddy, and M.Clayton. ‘Why We Should Allow Performance Enhancing Drugs in Sport’. British Journal of Sports Medicine38 (2004): 666–70. Pipe, A., and C.Ayotte. ‘Nutritional Supplements and Doping’. Clinical Journal of Sport Medicine12, no. 4 (2002): 245–9. Mason, C.B., and E.M.Lavallee. ‘Emerging Supplements in Sports’. Sports Health: A Multidisciplinary Approach4, no. 2 (2012): 142–6. Farah, M.J., C.Haimm, G.Sankoorikal, and A.Chatterjee. ‘When We Enhance Cognition with Adderall, Do We Sacrifice Creativity? A Preliminary Study’. Psychopharmacology202, no. 1 (2009): 541–7. Deventer, K., K.Roels, F.T.Delbeke, and P.van Eenoo. ‘Prevalence of Legal and Illegal Stimulating Agents in Sports’. Analytical and Bioanalytical Chemistry401, no. 2 (2011): 421–32. Jones, A.R., and J.T.Pichot. ‘Stimulant Use in Sports’. American Journal of Addiction7, no. 4 (1998): 243–55. Mottram, D.R., ed. Drugs in Sport., 5th ed.New York: Routledge, 2011. Mottram, D.R., ed. Drugs in Sport., 5th ed.New York: Routledge, 2011. Hemmersbach, P., and R.de la Torre. ‘Stimulants, Narcotics and β-Blockers: 25 years of Development in Analytical Techniques for Doping Control’. Journal of Chromatography B: Biomedical Sciences and Applications687, no. 1 (1996): 221–38. Repantis, D., P.Schlattmann, O.Laisney, and I.Heuser. ‘Modafinil and Methylphenidate for Neuroenhancement in Healthy Individuals: A Systematic Review’. Pharmacological Research62, no. 3 (2010): 187–206. Smith, M.E., and M.J.Farah. ‘Are Prescription Stimulants “Smart Pills”? The Epidemiology and Cognitive Neuroscience of Prescription Stimulant Use by Normal Healthy Individuals’. Psychological Bulletin137, no. 5 (2011): 717–41. Swanson, J.M., T.L.Wigal, and N.D.Volkow. ‘Contrast of Medical and Nonmedical Use of Stimulant Drugs, Basis for the Distinction, and Risk of Addiction: Comment on Smith and Farah’. Psychological Bulletin137, no. 5 (2011): 742–8. Volkow, N.D., G.Wang, J.S.Fowler, J.Logan, M.Gerasimov, L.Maynard, Y.Ding, S.J.Gatley, A.Gifford, and D.Franceschi. ‘Therapeutic Doses of Oral Methylphenidate Significantly Increase Extracellular Dopamine in the Human Brain’. Journal of Neuroscience21, no. 2 (2001): RC121-1–RC121-5. Cakic, V. ‘Smart Drugs for Cognitive Enhancement: Ethical and Pragmatic Considerations in the Era of Cosmetic Neurology’. Journal of Medical Ethics35 (2009): 611–75. Farah, M.J., J.Illes, R.Cook-Deegan, H.Gardner, E.Kandel, P.King, E.Parens, B.Sahakian, and P.R.Wolpe. ‘Neurocognitive Enhancement: What can We Do and What Should We Do?’. Nature Reviews: Neuroscience5 (2004): 421–5. Greely, H., B.Sahakian, J.Harris, R.C.Kessler, M.Gazzaniga, P.Campbell, and M.J.Farah. ‘Towards Responsible Use of Cognitive Enhancing Drugs by the Healthy’. Nature456 (2008): 702–5. Sahakian, B., and S.Morein-Zamir. ‘Professor's Little Helper’. Nature450 (2007): 1157–9. Boyd, C.J., S.E.McCabe, J.A.Cranford, and A.Young. ‘Prescription Drug Abuse and Diversion Among Adolescents in a Southeast Michigan School District’. Archives of Pediatrics Adolescent Medicine161, no. 3 (2007): 276–81. Fischer, B., M.Bibby, and M.Bouchard. ‘The Global Diversion of Pharmaceutical Drugs Non-Medical Use and Diversion of Psychotropic Prescription Drugs in North America: A Review of Sourcing Routes and Control Measures’. Addiction105, no. 12 (2010): 2062–70. Elliott, R., B.J.Sahakian, K.Matthews, A.Bannerjea, J.Rimmer, and T.W.Robbins. ‘Effects of Methylphenidate on Spatial Working Memory and Planning in Healthy Young Adults’. Psychopharmacology131, no. 2 (1997): 196–206. Schermer, M., I.Bolt, R.de Jongh, and B.Olivier. ‘The Future of Psychopharmacological Enhancements: Expectations and Policies’. Neuroethics2 (2009): 75–87. Farah, M.J., J.Illes, R.Cook-Deegan, H.Gardner, E.Kandel, P.King, E.Parens, B.Sahakian, and P.R.Wolpe. ‘Neurocognitive Enhancement: What can We Do and What Should We Do?’. Nature Reviews: Neuroscience5 (2004): 421–5. Repantis, D., P.Schlattmann, O.Laisney, and I.Heuser. ‘Modafinil and Methylphenidate for Neuroenhancement in Healthy Individuals: A Systematic Review’. Pharmacological Research62, no. 3 (2010): 187–206. Deventer, K., K.Roels, F.T.Delbeke, and P.van Eenoo. ‘Prevalence of Legal and Illegal Stimulating Agents in Sports’. Analytical and Bioanalytical Chemistry401, no. 2 (2011): 421–32. Swart, J., R.P.Lamberts, M.I.Lambert, StA.Clair Gibson, E.V.Lambert, J.Skowno, and T.D.Noakes. ‘Exercising with Reserve: Evidence that the Central Nervous System Regulates Prolonged Exercise Performance’. British Journal of Sports Medicine43, no. 10 (2009): 782–8. Roelands, B., H.Hasegawa, P.Watson, M.F.Piacentini, L.Buyse, G.De Schutter, and R.R.Meeusen. ‘The Effects of Acute Dopamine Reuptake Inhibition on Performance’. Medicine & Science in Sports & Exercise40, no. 5 (2008): 879–85. Repantis, D., P.Schlattmann, O.Laisney, and I.Heuser. ‘Modafinil and Methylphenidate for Neuroenhancement in Healthy Individuals: A Systematic Review’. Pharmacological Research62, no. 3 (2010): 187–206. Kaufman, K.R. ‘Modafinil in Sports: Ethical Considerations’. British Journal of Sports Medicine39, no. 4 (2005): 241–4. Repantis, D., P.Schlattmann, O.Laisney, and I.Heuser. ‘Modafinil and Methylphenidate for Neuroenhancement in Healthy Individuals: A Systematic Review’. Pharmacological Research62, no. 3 (2010): 187–206. Wesensten, N., G.Belenky, M.A.Kautz, D.R.Thorne, R.M.Reichardt, and T.J.Balkin. ‘Maintaining Alertness and Performance During Sleep Deprivation: Modafinil Versus Caffeine’. Psychopharmacology159, no. 3 (2002): 238–47. Kaufman, K.R. ‘Modafinil in Sports: Ethical Considerations’. British Journal of Sports Medicine39, no. 4 (2005): 241–4. Williams, S.J., C.Seale, S.Boden, P.Low, and D.L.Steinberg. ‘Waking Up to Sleepiness: Modafinil, the Media and the Pharmaceuticalisation of Everyday/Night Life’. Sociology of Health & Illness30, no. 6 (2008): 839–55. Jacobs, I., and D.G.Bell. ‘Effects of Acute Modafinil Ingestion on Exercise Time to Exhaustion’. Medicine and Science in Sports Exercise36, no. 6 (2004): 1078–82. Repantis, D., P.Schlattmann, O.Laisney, and I.Heuser. ‘Modafinil and Methylphenidate for Neuroenhancement in Healthy Individuals: A Systematic Review’. Pharmacological Research62, no. 3 (2010): 187–206. Greely, H., B.Sahakian, J.Harris, R.C.Kessler, M.Gazzaniga, P.Campbell, and M.J.Farah. ‘Towards Responsible Use of Cognitive Enhancing Drugs by the Healthy’. Nature456 (2008): 702–5. Farah, M.J., C.Haimm, G.Sankoorikal, and A.Chatterjee. ‘When We Enhance Cognition with Adderall, Do We Sacrifice Creativity? A Preliminary Study’. Psychopharmacology202, no. 1 (2009): 541–7. Farah, M.J., C.Haimm, G.Sankoorikal, and A.Chatterjee. ‘When We Enhance Cognition with Adderall, Do We Sacrifice Creativity? A Preliminary Study’. Psychopharmacology202, no. 1 (2009): 541–7. White, N.M. ‘Cognitive Enhancement: An Everyday Event?’. International Journal of Psychology33, no. 2 (1998): 95–105. White, N.M. ‘Cognitive Enhancement: An Everyday Event?’. International Journal of Psychology33, no. 2 (1998): 95–105. Jones, A.R., and J.T.Pichot. ‘Stimulant Use in Sports’. American Journal of Addiction7, no. 4 (1998): 243–55. Roelands, B., and R.Meeusen. ‘Alterations in Central Fatigue by Pharmacological Manipulations of Neurotransmitters in Normal and High Ambient Temperature’. Sports Medicine40, no. 3 (2010): 229–43. Avois, L., N.Robinson, C.Saudan, N.Baume, P.Mangin, and M.Saugy. ‘Central Nervous System Stimulants and Sport Practice’. British Journal of Sports Medicine40, no. 1 (2006): i16–i20. Deventer, K., K.Roels, F.T.Delbeke, and P.van Eenoo. ‘Prevalence of Legal and Illegal Stimulating Agents in Sports’. Analytical and Bioanalytical Chemistry401, no. 2 (2011): 421–32. Jones, A.R., and J.T.Pichot. ‘Stimulant Use in Sports’. American Journal of Addiction7, no. 4 (1998): 243–55. Mottram, D.R., ed. Drugs in Sport., 5th ed.New York: Routledge, 2011. WADA. ‘The World Anti-Doping Code: The 2011 Prohibited List International Standard’. 2011, http://www.wada-ama.org. Avois, L., N.Robinson, C.Saudan, N.Baume, P.Mangin, and M.Saugy. ‘Central Nervous System Stimulants and Sport Practice’. British Journal of Sports Medicine40, no. 1 (2006): i16–i20. Magkos, F., and S.A.Kavouras. ‘Caffeine and Ephedrine Physiological, Metabolic and Performance-Enhancing Effects’. Sports Medicine34, no. 13 (2004): 871–89. Moolenaar, M., P.A.Desmond, D.J.Mascord, G.A.Starmer, B.Tattam, and E.R.Volkerts. ‘The Effects of Ephedrine on the Development of Fatigue in a Prolonged Driving-Related Task’. Human Psychopharmacology: Clinical & Experimental14, no. 6 (1999): 415–27. Avois, L., N.Robinson, C.Saudan, N.Baume, P.Mangin, and M.Saugy. ‘Central Nervous System Stimulants and Sport Practice’. British Journal of Sports Medicine40, no. 1 (2006): i16–i20. Eichner, E.R. ‘Stimulants in Sports’. Current Sports Medicine Reports7, no. 5 (2008): 244–5. Bell, D.G., I.Jacobs, and J.Zamecnik. ‘Effects of Caffeine, Ephedrine and Their Combination on Time to Exhaustion During High-Intensity Exercise’. European Journal of Applied Physiology and Occuputional Physiology77, no. 5 (1998a): 427–33. Bell, D.G., T.M.McLellan, and C.M.Sabiston. ‘Effect of Ingesting Caffeine and Ephedrine on 10-km Run Performance’. Medicine and Science in Sports Exercise34, no. 2 (1998b): 344–9. Hodges, K., S.Hancock, K.Currell, B.Hamilton, A.E.Jeukendrup. ‘Pseudoephedrine Enhances Performance in 1500-m Runners’. Medicine and Science in Sports Exercise38, no. 2 (2006): 329–33. Bohn, A.M., M.Khodaee, and T.L.Schwenk. ‘Ephedrine and Other Stimulants as Ergogenic Aids’. Current Sports Medicine Reports2, no. 4 (2003): 220–5. Magkos, F., and S.A.Kavouras. ‘Caffeine and Ephedrine Physiological, Metabolic and Performance-Enhancing Effects’. Sports Medicine34, no. 13 (2004): 871–89. Bohn, A.M., M.Khodaee, and T.L.Schwenk. ‘Ephedrine and Other Stimulants as Ergogenic Aids’. Current Sports Medicine Reports2, no. 4 (2003): 220–5. Magkos, F., and S.A.Kavouras. ‘Caffeine Use in Sports, Pharmacokinetics in Man, and Cellular Mechanisms of Action’. Critical Reviews in Food Science and Nutrition45 (2005): 535–62. Sinclair, C.J.D., and J.D.Geiger. ‘Caffeine Use in Sports: A Pharmacological Review’. Journal of Sports Medicine and Physical Fitness40, no. 1 (2000): 71–9. Burke, L.M. ‘Caffeine and Sports Performance’. Applied Physiology, Nutrition, and Metabolism33 (2008): 1319–94. Wesensten, N., G.Belenky, M.A.Kautz, D.R.Thorne, R.M.Reichardt, and T.J.Balkin. ‘Maintaining Alertness and Performance During Sleep Deprivation: Modafinil Versus Caffeine’. Psychopharmacology159, no. 3 (2002): 238–47. Richardson, N.J., P.J.Rogers, N.A.Elliman, and R.J.O'Dell. ‘Mood and Performance Effects of Caffeine in Relation to Acute and Chronic Caffeine Deprivation’. Pharmacology Biochemistry and Behavior52, no. 2 (1995): 313–20. Doherty, M., and P.H.Smith. ‘Effects of Caffeine Ingestion on Rating of Perceived Exertion during and after Exercise: A Meta-Analysis’. Scandinavian Journal of Medicine and Science in Sports15 (2005): 69–78. Burke, L.M. ‘Caffeine and Sports Performance’. Applied Physiology, Nutrition, and Metabolism33 (2008): 1319–94. WADA. ‘The World Anti-Doping Code: The 2011 Prohibited List International Standard’. 2011, http://www.wada-ama.org. Roelands, B., and R.Meeusen. ‘Caffeine, Dopamine and Thermoregulation’. European Journal of Applied Physiology112 (2012): 1979–80. Noakes, T.D. ‘Time to Move Beyond a Brainless Exercise Physiology: The Evidence for Complex Regulation of Human Exercise Performance’. Applied Physiology Nutrition and Metabolism36, no. 1 (2011): 23–35. Hall, W.D., and J.C.Lucke. ‘The Enhancement Use of Neuropharmaceuticals: More Scepticism and Caution Needed’. Addiction105, no. 12 (2010): 2041–3. Mottram, D.R., ed. Drugs in Sport., 5th ed.New York: Routledge, 2011. Eichner, E.R. ‘Stimulants in Sports’. Current Sports Medicine Reports7, no. 5 (2008): 244–5. Hall, W. ‘Feeling “Better than Well”’. EMBO Reports5, no. 12 (2004): 1105–9. WADA. ‘The World Anti-Doping Code: The 2011 Prohibited List International Standard’. 2011, http://www.wada-ama.org. Maher, B. ‘Poll Results: Look who's Doping’. Nature452 (2008): 674–5. Johnston, L.D., P.M.O'Malley, J.G.Bachman, and J.E.Schulenberg. Monitoring the Future National Survey Results on Drug Use, 1975–2010: Volume II, College Students and Adults Ages 19–50. (NIH Publication No. 10–7585). Bethesda: National Institute on Drug Abuse, Table 5-2, Table 2-2. http://monitoringthefuture.org/pubs.html2011. Mottram, D.R., ed. Drugs in Sport., 5th ed.New York: Routledge, 2011. Outram, S.M. ‘The Future of Enhancement? The Use of Methylphenidate Among Students’. Journal of Medical Ethics36 (2010): 198–202. Downie, J., S.M.Outram, and F.Campbell. ‘Caveat Emptor, Venditor, Et Praescribor: Legal Liability Associated with Methylplenidate Hydrochloride (MPH) Use by Postsecondary Students’. Health Law Journal18 (2010): 51–71. Barrett, S.P., C.Darredeau, L.E.Bordy, and R.O.Pihl. ‘Characteristics of Methylphenidate Misuse in a University Student Sample’. Canadian Journal of Psychiatry50, no. 8 (2005): 457–61. McCabe, S.E., C.J.Boyd, and C.J.Teter. ‘Subtypes of Nonmedical Prescription Drug Misuse’. Drug and Alcohol Dependence102 (2009): 63–70. White, B.P., K.A.Becker-Blease, and K.Grace-Bishop. ‘Stimulant Medication Use, Misuse, and Abuse in an Undergraduate and Graduate Student Sample’. Journal of American College Health54, no. 5 (2006): 261–8. Forlini, C., and E.Racine. ‘Autonomy and Coercion in Academic “Cognitive Enhancement” Using Methylphenidate: Perspectives of Key Stakeholders’. Neuroethics2 (2009): 163–77. Hemphill, D. ‘Performance Enhancement and Drug Control in Sport: Ethical Considerations’. Sport in Society12, no. 3 (2009): 313–26. Petróczi, A., J.Mazanov, T.Nepusz, S.H.Backhouse, and D.P.Naughton. ‘Comfort in Big Numbers: Does Over-estimation of Doping Prevalence in Others Indicate Self-involvement?’. Journal of Occupational Medicine and Toxicology3 (2008): 19e. Petróczi, A., and E.Aidman. ‘Psychological Drivers in Doping: The Life-Cycle Model of Performance Enhancement’. Substance Abuse Treatment, Prevention, and Policy3 (2008): 7e. McDuff, D.R., and D.Baron. ‘Substance Use in Athletics: A Sports Psychiatry Perspective’. Clinical Journal of Sports Medicine24, no. 4 (2005): 885–97. Berning, J.M., K.J.Adams, and B.A.Stamford. ‘Anabolic Steroid Usage in Athletics: Facts, Fiction, and Public Relations’. Journal of Strength and Conditioning Research18, no. 4 (2004): 908–17. Outram, S.M. ‘The Future of Enhancement? The Use of Methylphenidate Among Students’. Journal of Medical Ethics36 (2010): 198–202. Partridge, B.J., S.K.Bell, J.C.Lucke, S.Yeates, and W.D.Hall. ‘Smart Drugs “As Common As Coffee”: Media Hype about Neuroenhancement’. PLoS ONE6, no. 11 (2011): 28416e. Petróczi, A., and E.Aidman. ‘Psychological Drivers in Doping: The Life-Cycle Model of Performance Enhancement’. Substance Abuse Treatment, Prevention, and Policy3 (2008): 7e. Mottram, D.R., ed. Drugs in Sport., 5th ed.New York: Routledge, 2011. König, E. ‘Criticism of Doping: The Nihilistic Side of Technological Sport and the Antiquated View of Sport Ethics’. International Review for the Sociology of Sport30, no. 3 and 4 (1995): 247–60. Parens, E. ‘Authenticity and Ambivalence: Towards Understanding the Enhancement Debate’. Hastings Center Reports35 (2005): 34–41. Savulescu, J. ‘Justice, Fairness, and Enhancement’. Annals of the New York Academy of Sciences1093 (2006): 321–38. Flower, K., L.Li1, C.-Y.A.Chen, M.J.Baggott, and G.P.Galloway. ‘Efficacy, Safety, and Ethics of Cosmetic Neurology Far From Settled’. Clinical Pharmacology & Therapeutics88, no. 4 (2010): 461–2. Williams, S.J., J.Gabe, and P.Martin. ‘The Pharmaceuticalisation of Society? A Framework for Analysis’. Sociology of Health & Illness33, no. 5 (2011): 710–25. Williams, S.J., J.Gabe, and P.Martin. ‘The Pharmaceuticalisation of Society? A Framework for Analysis’. Sociology of Health & Illness33, no. 5 (2011): 710–25.